Bharat Biotech’s Covaxin too gets nod for emergency use
Saturday, 2 January 2021 () India's vaccine rollout will begin with the availability of two jabs- Oxford-Astra Zeneca's Covishield and Bharat Biotech's homegrown Covaxin- with the Drugs Controller General of India expected to issue final approvals on Sunday. Covishield maker Serum Institute has offered a price of Rs 225-250 per dose for the first tranche, whereas Bharat Biotech has offered Rs 350, a source said.
Congress leader Manish Tewari alleged that the union government has 'politically misused pandemic in its entirety'. Tewari also slammed the Centre over the grant of approval to Bharat Biotech's Covid vaccine. The congress leader, however, did not name the Hyderabad-based company. On Sunday, DCGI...
At least 1,65,714 healthcare beneficiaries received COVID-19 jab on Saturday across India, marking it as a historic and biggest COVID-19 vaccination drive launched by Prime Minister Narendra Modi. About 16,755 total vaccinators involved across India during the COVID vaccination drive. There was no post adverse event reported after the vaccination was administered to the people. "Total vaccinators involved across India were 16,755. Total beneficiaries vaccinated across India--1,65,714. COVID19 vaccination drive was successful on Day 1. No case of post-vaccination hospitalisation reported so far," said Manohar Agnani, Additional Secretary of Union Health Ministry. "The Serum Institute of India (SII) produced COVISHIELD was supplied to all States and Union Territories (UT). Bharat Biotech's COVAXIN was supplied to 12 States. Total 3,351 sessions were held across the country with both the vaccines, said Health Ministry on COVID19 vaccine roll-out," he added. Watch the full video for more details.
Credit: HT Digital Content Duration: 06:46Published
On Day 1 of India's Covid-19 vaccination, two doctors who took the shots shared their experience. Dr Atul Peters and Anil Dhar of Max hospital were given Bharat Biotech's Covaxin and SII-made Covishield jabs respectively. Both didn't experience any side-effects and said that doubts regarding the inoculants are unfounded. Dr Suranjit Chatterjee of Apollo hospital, who is set to receive a shot soon, also weighed in on the controversy regarding Covaxin and its third phase trials. Watch the full video for more.
Credit: HT Digital Content Duration: 08:15Published
Urging the people to have faith in India's researchers, scientists, regulatory authorities, All India Institute of Medical Sciences (AIIMS) Director Dr Randeep Singh Guleria on Saturday reassured the nation that Bharat Biotech's COVAXIN vaccine is safe. Dr Guleria along with NITI Aayog member VK Paul were administered the COVID-19 vaccine shot at AIIMS Delhi on the inaugural day of the nationwide roll-out of vaccination on Saturday. Talking about the experience, he said, "I am humbled to get vaccinated in the first slot and feel so proud. I hope more and more people come forward when it comes to getting vaccinated so that we can reduce mortality and prevent the spread of COVID-19 infection." Dr VK Paul said that the vaccine is safe and people should trust the scientific process. Watch the full video for more details.
Credit: HT Digital Content Duration: 03:41Published
Congress leader Manish Tewari has lashed out at the government over the approval given to Covaxin for the first phase of trials. The Congress leader raised questions over the efficacy of the indigenously developed Covaxin, which is in the third phase of trials and has been cleared for restricted emergency use by the Drugs Controller General of India. ‘Government should act in a manner whereby there's complete confidence in people. You can't use rollout as phase 3 trial, Indians are not guinea pigs,’ Manish Tewari said. The former minister’s remarks come after government hinted that people will not be allowed to choose from the two vaccines recently approved. The first phase of coronavirus vaccination is all set to begin on 16th January, 2021. Watch the full video for all the details.
Credit: HT Digital Content Duration: 01:40Published
The Government of India announced the launch date of its mass immunisation programme against Covid-19. The vaccinations will begin on January 16, 2021. On January 3, India's drug regulator DCGI had cleared 2 vaccines - Covaxin and Covishield - for emergency use. Covaxin, made by Bharat Biotech, will be used under clinical trial conditions, as per the government. Covishield was developed by Oxford university and pharma major AstraZeneca, and is being made in India by Serum Institute of India (SII). Around 30 crore people are being targeted for vaccination in phase 1. These include healthcare staff, frontline workers like police, those aged above 50, and those aged below 50 but with co-morbidities. Watch the full video for more.
Credit: HT Digital Content Duration: 01:34Published
After Nepal government approved emergency use of Covishield vaccine, people are hoping the pandemic will falter and human lives would be back on track. Nepal's Department of Drug Administration on Friday issued a release giving information on approving Covishield developed by AstraZeneca and Oxford University, which will be manufactured by Serum Institute of India (SII) in India. Drug regulating authority has also specified Serum Institute of India for importers provided with low cost in purchasing and delivery of vaccine to public. Approving the vaccine for conditional purpose, the department has also asked manufacturers or importers to get approval for registration in order to bring the vaccines. Nepal imposed nationwide and partial lockdown for most of 2020 with rise in imported cases which later took the form of local transmission spreading mostly in urban areas and major cities. The nationwide lockdown which started in March 2020 hampered daily life of people as well as businesses. They now expect to thrive with the approval of vaccine. Though the detailed inoculation plan of Nepal Government is yet to be disclosed, a total of 3 companies applied for approval to take steps forward with Serum Institute for import of vaccines. India has already made conditional emergency approval for Covishield manufactured by the Serum Institute. Being one of the largest producers of vaccines at low cost, India has promised to provide vaccine to its neighbours in near future.
82-year-old Victoria Watling became the first person to receive the coronavirus vaccine at the Boots pharmacy in Halifax. Boots and Superdrug branches are among the six stores across England which started administering the Covid vaccine today. Clinical pharmacist Bhavika Mistry, who administered the Oxford AstraZeneca jab spoke of the importance of opening smaller hubs around the country which she said are “more accessible” to local communities. Report by Blairm. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Bharat Biotech has said that it will pay recipients of the vaccine Covaxin compensation if beneficiaries face any adverse effects after taking it while the vaccine remains in clinical trial mode. Watch..
Delhi Chief Minister Arvind Kejriwal commented on the impending launch of mass immunisation against Covid-19. India will begin vaccinations on January 16. Vaccines are being shipped to various centres..
Credit: HT Digital Content Duration: 02:39Published